Fuda Cancer Hospital
Fuda Cancer Hospital
China, Cantão
| China | Turquia | Áustria | |
| Tomoterapia | de $17,500 | de $12,000 | de $30,000 |
| Terapêutica hormonal | de $3,500 | de $402 | de $7,000 |
| Terapia de protão | de $36,500 | de $70,000 | de $80,000 |
| Terapia de privação de androgénios | de $3,800 | de $1,500 | de $4,500 |
| Sistema Robótico Da Vinci | de $24,500 | de $9,500 | de $22,000 |
A Bookimed não adiciona taxas extras aos preços de tratamento de Cancro da próstata. As tarifas vêm das listas oficiais de preços das clínicas. O pagamento é feito diretamente na clínica na chegada ao país.
A Bookimed está comprometida com sua segurança. Trabalha apenas com instituições que mantêm altos padrões internacionais no tratamento de Cancro da próstata e têm as licenças necessárias para atender pacientes internacionais em todo o mundo.
A Bookimed oferece assistência gratuita de especialistas. Um coordenador médico pessoal apoia antes, durante e após o tratamento, solucionando problemas. Nunca está sozinho em sua jornada de tratamento de Cancro da próstata.
Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.
He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.
His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.
O Dr. Lo Zhunchen traz mais de 20 anos de experiência médica para o tratamento do cancro da próstata no Fuda Cancer Hospital.
Top-rated hospitals for prostate cancer in China include JCI-accredited centers like Fuda Cancer Hospital and Yanda International Hospital. These facilities specialize in minimally invasive techniques and robotic surgery. Public academic giants in Beijing and Shanghai also lead in research and high surgical volumes.
Bookimed Expert Insight: While public hospitals handle massive volumes, JCI-accredited centers like Yanda International Hospital provide a unique bridge for international patients. Our data shows these facilities combine Western surgical protocols with traditional Chinese approaches. This integration is particularly useful for managing treatment side effects. Yanda also holds the Class A Level III designation. This is the highest medical ranking achievable in the Chinese healthcare system.
Patient Consensus: Patients note that major city hospitals offer robotic systems which improve recovery. Many suggest hiring a translator as English support can be limited during follow-up Care.
China offers advanced prostate cancer care through robotic systems and specialized particle radiation therapies. Facilities utilize 5G-enabled telesurgery and Carbon Ion Radiotherapy to treat complex cases. These technologies reach high-risk tumors with precise energy while protecting surrounding healthy tissue and critical urinary functions.
Bookimed Expert Insight: Patient data shows a shift toward specialized non-surgical centers like Fuda Cancer Hospital in Guangzhou. This facility has treated over 30,000 international patients using 10+ types of minimally invasive therapies. Their focus on microwave hyperthermia and vascular intervention offers alternatives for those seeking to avoid traditional chemotherapy.
Patient Consensus: Patients value the availability of the NanoKnife system for its ability to treat tumors near sensitive nerves. Many note that the high volume of international cases at JCI-accredited hospitals makes the coordination of complex radiation schedules much smoother.
Metastatic prostate cancer management in China centers on aggressive multimodal protocols combining androgen deprivation therapy with specialized minimally invasive techniques. Advanced centers utilize cryosurgery, NanoKnife, and vascular interventional therapy. These approaches complement international standards like hormonal manipulation and chemotherapy for late-stage cases.
Bookimed Expert Insight: China's top oncology centers like Fuda Cancer Hospital and Yanda International Hospital stand out by treating approximately 2,500,000 patients annually with 30,000+ international cases. Data shows these JCI-accredited facilities often prioritize organ-sparing technologies over radical surgery for metastatic patients. Patients seeking care in Beijing or Guangzhou can access specialists like Dr. Lo Zhunchen, who has over 20 years of experience in complex hematology and oncology protocols.
Patient Consensus: Patients note that top-tier hospitals provide faster access to advanced PSMA-targeted therapies and clinical trials compared to Western countries. It is important to confirm genomic testing for BRCA mutations before starting combination treatments to ensure the most effective therapy plan.
Traditional Chinese Medicine (TCM) serves as a complementary therapy for prostate cancer in China. It improves survival rates and manages treatment side effects alongside conventional care. Specific formulations like Xihuang Pills reduce chemotherapy-induced pain. TCM also helps inhibit tumor progression and may reduce bone metastasis risk.
Bookimed Expert Insight: While many search for TCM as a primary cure, China’s high-volume Class A Level III hospitals like Yanda International Hospital focus on a hybrid model. They integrate 28,500 modern technologies with traditional approaches. This suggests the most effective path is using TCM specifically for recovery and symptom control, rather than replacing standard oncology protocols. Combining international surgical standards with local herbal recovery may explain why these centers successfully manage 2,500,000 patients annually.
Patient Consensus: Patients note that TCM is most effective for relieving urinary issues and boosting energy after surgery or radiation. Many emphasize the importance of consulting a Western oncologist first, as certain herbs can cause unexpected PSA spikes or interfere with hormone medications.